Compass Therapeutics, Inc.

NASDAQ•CMPX

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-04-05

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Contact Information

80 Guest Street, Suite 601, Boston, MA, 02135, United States

617-500-8099

www.compasstherapeutics.com

Market Cap

$253.06M

P/E (TTM)

-5.0

22.3

Dividend Yield

52W High

$6.88

52W Low

$1.61

52W Range

Rank65Top 96.0%

1.6

F-Score

Modified Piotroski Analysis

Based on 7-year fundamentals

Weak • 1.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2019-2025

Financial Dashboard

Q1 2026 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.10+0.00%

4-Quarter Trend

FCF

-$17.35M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Tovecimig Trial Endpoint Met Tovecimig met primary endpoint in BTC Phase 2/3 trial, showing 17.1% ORR versus 5.3% for paclitaxel alone (p=0.031).

R&D Investment Increased Research and development expenses increased $13.6M to $56.0M in 2025, supporting four clinical stage product candidates.

Cash Runway Into 2028 Cash, equivalents, and marketable securities totaled $209M as of December 31, 2025, funding operations into 2028.

Risk Factors

Continued Operating Losses Net loss widened $16.3M to $66.5M for 2025, reflecting substantial ongoing operating expenses and accumulated deficit.

Clinical Development Uncertainty Clinical development is lengthy, expensive, with uncertain outcomes; failure risks material harm to prospects and pipeline.

Substantial Financing Required Substantial additional financing required to pursue objectives; failure to secure capital could terminate development efforts.

Outlook

Tovecimig Data Readout Expected Expect top-line progression-free survival and overall survival data from US BTC Phase 2/3 trial in April 2026.

CTX-471 Phase 2 Initiation Plan to initiate Phase 2 basket study for CTX-471 in mid-2026, utilizing NCAM as a selection biomarker.

CTX-10726 Clinical Start Phase 1 dose escalation study for CTX-10726, following IND clearance, is expected to begin enrollment in Q1 2026.

Peer Comparison

Revenue (TTM)

RGNX

$170.44M

+104.5%

FDMT

$88.24M

+383560.9%

MGTX

$81.39M

+144.6%

Gross Margin (Latest Quarter)

ATXS

100.0%

+0.0pp

BCYC

100.0%

+1705.8pp

LXRX

99.5%

+4.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
KOD	$2.11B	-10.7	-253.8%	18.3%
MLTX	$1.37B	-5.2	-85.2%	25.2%
KALV	$1.37B	-8.3	-436.7%	0.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 13, 2026

EPS:-$0.09

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data